
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Treating AML With Myelodysplasia-Related Changes
Case: A 68-Year-Old Man With Newly-diagnosed AML

